TABLE OF CONTENTS
KEY
🔍 | Deep Dive |
📌 | Clinical Application |
🔸 | Weak Evidence |
🔹 | Strong Evidence |
📑 | Evidence summaries |
✅ | Recommended treatment |
⚠️ | Critical Information |
💡 | Extra Reading |
❗ | Caveats |
This article comes from a mistake I made. Or maybe a mistake I keep making regularly.
Waiting.
Waiting for a creatinine report before sending a patient for a contrast-enhanced CT in the emergency department. Because what if I cause contrast nephropathy? So I went down a rabbit hole. And what I found surprised me.
Where did this fear even come from?
The idea of contrast nephropathy dates back to the 1950s, when patients developed renal failure after contrast studies like intravenous pyelography. But back then, contrast agents were very different. Also, evidence-based medicine wasn’t really a thing yet. But the idea stuck.
Once the myth took hold, we started labelling every rise in creatinine after a contrast CT as “contrast-induced nephropathy.” But in reality, that rise could have been due to a multitude of other factors.
We assumed causation without actually proving it.
What even is “Contrast Nephropathy”?
Traditionally, contrast nephropathy was defined as any increase in creatinine after contrast exposure
The underlying assumption? Even a small bump in creatinine must represent real kidney injury, and it actually matters clinically.
But that assumption is questionable.
Modern definitions are more cautious. Over time, experts realised we were being a bit too confident about causation.
KDIGO proposed the term “contrast-induced acute kidney injury (CI-AKI)” and defined it as a rise in serum creatinine of ≥0.5 mg/dL (44 μmol/L) or a ≥25% increase from baseline, measured within 48 hours of a contrast study.
But these definitions only tell us what happened, not why it happened.
But later, KDIGO introduced the term “Contrast-associated acute kidney injury”, accepting that in many cases AKI may or may not be solely attributable to contrast. [2]
While AKI itself is defined as
Functional criteria | Structural criteria |
• Increase in SCr by ≥0.3 mg/dl within 48 hours • Increase in SCr or serum cystatin C by ≥1.5 times baseline, that is known/presumed to have occurred within the prior 7 days • Mean urine volume of less than 0.5 ml/kg/h for ≥6 hours | Elevation of a biomarker of kidney damage which ismknown or presumed to have occurred within the prior 7 days |
The American College of Radiology (ACR) also agree that we stop using the term contrast-induced nephropathy (CIN) so casually. They made the important distinction that CI-AKI is a causative diagnosis while CA-AKI is a correlative diagnosis [3].
The important shift: correlation ≠ causation
So, is contrast nephropathy real?
Unfortunately, it would be unethical to perform a true prospective RCT to definitively answer this question. But over the past decade, numerous studies and meta-analyses have emerged, and most of them don’t find any meaningful relationship between contrast administration and kidney injury.
To really answer the question of contrast nephropathy, we need to ask three things:
1. Does contrast increase creatinine?
Across multiple large studies:
- No difference in AKI, dialysis, or mortality between contrast and non-contrast CT groups
- Pre-existing chronic kidney disease is the strongest patient-related risk factor. However, even in this group, intravenous contrast was not associated with an increased risk of AKI.
- Same findings in sepsis, critically ill patients and the ED population.
A meta-analysis even showed similar AKI rates in contrast and non-contrast CT, suggesting other factors are responsible. [1,7-18]
Some studies do report a small signal. There appears to be a minimal risk of CIN in mild to moderate renal dysfunction [19]
2. Does that increased creatinine really reflect renal injury?
This is where things get even more interesting [13,22]
- Creatinine fluctuates naturally, even without contrast
- Studies show no change in kidney injury biomarkers (KIM-1, NGAL) after contrast
- In the many cohorts, the mean creatinine doesn’t change [18,20-21]
Which is interesting because if the average doesn’t change, but a few patients go up, a few must also be going down. This starts to look less like pathology and more like random fluctuation.
Interestingly, KDIGO provides a detailed list of nephrotoxins. Contrast isn’t explicitly mentioned. But many drugs we use quite casually are:
- Trimethoprim
- Cimetidine
- Corticosteroids
- Cephalosporins
- Colistin
- Vancomycin
- PPIs
- NSAIDs
- Acyclovir
- Diuretics
We worry a lot about the contrast of a theoretical nephrotoxin. But routinely prescribe drugs that are well-established nephrotoxins. That mismatch is worth thinking about.
3. Does it actually affect patient outcomes?
Even if creatinine rises [7, 15,20,23]
- No increase in dialysis rates
- No increase in mortality
- No worsening of clinical outcomes
Even in patients with pre-existing CKD, contrast was not associated with worse outcomes.
ACR (2025) notes that when creatinine does rise after contrast, the course is usually mild and transient. It begins within 24 hours, peaks by around day 4 and returns to baseline within 7–10 days. Permanent renal dysfunction is unusual.
Is there a pathophysiological basis?
The exact mechanism by which contrast might cause kidney injury is not entirely clear. But a few theories do exist. [4]
- Direct toxicity: Contrast agents are thought to have a direct toxic effect on tubular epithelial cells. This can lead to: loss of function, apoptosis or even necrosis.
- Indirect Injury: A lot of the proposed injury is actually indirect. Contrast can cause vasomotor changes mediated by substances like endothelin, nitric oxide and prostaglandins. This leads to reduced renal blood flow and, consequently, ischemia. Since the outer medulla of the kidney already lives on the edge, with low oxygen tension and high metabolic demand, even small hemodynamic changes can tip it into injury.
While all of this sounds convincing. We must know that these mechanisms are theoretical and lab-based and don’t consistently translate into clinically significant injury in real patients
Also, all contrasts are not the same
There are three categories of iodinated contrast:
- High-osmolar contrast (~1500 mOsm)
Diatrizoate (Hypaque, Gastrografin), iothalamate
- Low-osmolar contrast (320–800 mOsm)
Iohexol, ioxaglate, ioversol, iomeprol, iopromide, iopamidol
- Iso-osmolar contrast (~290 mOsm)
Iodixanol
Although we don’t have placebo-controlled trials proving the existence of CIN, we do have randomised trials comparing these agents with each other.
🔹 Compared to older high-osmolar contrast agents, modern low- and iso-osmolar agents are associated with a lower risk of kidney injury. Because of this, their use is strongly recommended by major societies, including the ESC and AHA–ACC.
While ACR and the National Kidney Foundation say
There are no confirmed clinically relevant differences in risk of CA-AKI between low-osmolality contrast media and iso-osmolarity contrast media for intravenous applications.
Which brings us back to the bigger question: Are we comparing small differences in risk for a problem that may not even be clinically significant?
What about CKD patients?
Interestingly, contrast-associated AKI has been linked to increased mortality and progression of CKD. The ACR and the National Kidney Foundation suggest that
- The risk of CA-AKI increases with each stepwise increase in CKD stage
- The risk of CI-AKI is substantially less than the risk of CA-AKI, but the actual risk remains uncertain in patients with severe kidney disease.
ACR guidance on using contrast in CKD patients is this
- Patients with anuric end-stage kidney disease can receive contrast without risk of further renal damage because there’s essentially no residual kidney function to lose.
- But there’s a nuance. In patients who are not completely anuric (still making urine):
- There is a theoretical risk of pushing them from oliguric → anuric
- But this remains unproven and speculative
- So practically: Patients on dialysis who still make >200–400 mL urine/day should be treated as high-risk.
- But do not start dialysis or change dialysis schedules just because contrast was given. There is no proven benefit, and it only adds risk and cost.
We will probably never be able to prove with 100% certainty that contrast isn’t nephrotoxic, which would require an impractical RCT. But based on current evidence, if it is nephrotoxic at all, it is likely an extremely weak nephrotoxin with little clinical relevance.
Hence, the ACR / National Kidney Foundation guidance states that patients with CKD stages 4 or 5 have a relative rather than an absolute contraindication to iodinated contrast media. If contrast media administration is required for a life-threatening diagnosis, then it should not be withheld based on kidney function
Risk–benefit balance
So it really comes down to this, balancing the risk vs benefit of giving IV contrast for a CT.
ACR says there is no agreed-upon threshold of serum creatinine elevation or eGFR decline beyond which the risk of CI-AKI is considered so great that intravascular iodinated contrast medium should never be administered. In fact, since each contrast medium administration always implies a risk-benefit analysis for the patient, contrast medium administration for all patients should always be taken in the clinical context, considering all risks, benefits and alternatives.
Right now, that calculation looks like:
- Risk of contrast: No strong, high-quality evidence that this risk meaningfully exists
- Benefit of contrast: Often immediate, real, and clinically important
ACR 2025 guidance suggests renal function assessment before the intravascular administration of iodinated contrast medium for these patients when done in the ED
- Personal history of renal disease
- History of diabetes mellitus (optional)
- Metformin or metformin-containing drug combinations
Ignoring the harms of not using contrast
We can’t talk about the harms of contrast without also talking about the harms of not using it. We often withhold essential tests because of the fear of CIN. Patients with CKD get non-contrast scans when contrast was actually needed, or we order V/Q scans when a CTPA would have been the better test. We don’t have great numbers to quantify this harm, but it clearly exists.
There’s also the system-level cost. Patients wait, often for hours, for creatinine results before getting a scan. That delay can mean delayed diagnosis and delayed treatment. And even when it doesn’t, it adds to ED crowding and keeps patients longer in an already stressful environment.
Now that we know all this… we will probably still wait for the creatinine. Because as doctors, we are wired to be risk-averse.
So here is what we can do
Step 1: Confirm the indication
Ask a simple question first: Will contrast change diagnosis or management?
It's important to remember ACR guidance here
Even in high-risk patients (AKI or eGFR <30 not on dialysis), concern for CI-AKI is a relative, not absolute contraindication to contrast. If alternative imaging (non-contrast CT, ultrasound, MRI) can answer the question, then contrast can be avoided. But in some situations, contrast is necessary regardless of CI-AKI risk.
If contrast media administration is required for a life-threatening diagnosis, then it should not be withheld based on kidney function
If it is a time-critical emergency scan where there is no reasonable alternate modality, proceed with the contrast study; do not wait for the creatinine report
Step 2: Assess risk
Risk is not a single number. It comes from a combination of patient and procedural factors.
Patient-related factors | Procedure-related factors |
Reduced GFR (especially <30 mL/min/1.73 m²) | High-osmolar contrast |
Diabetes mellitus | Large volume of contrast |
Hypovolemia | Serial contrast exposure |
Concurrent nephrotoxic medications | Intra-arterial administration |
One of the ways to approach and stratify risk is the use of the Choyke questionnaire to identify patients with a higher risk of abnormal renal function
- Has any doctor ever told you that you have kidney problems?
- Has any doctor ever told you that you have protein in your urine (proteinuria)?
- Do you have high blood pressure (hypertension)?
- Do you have diabetes?
- Do you have gout?
- Have you ever had kidney surgery?
CW too et al concluded that the Choyke questionnaire has excellent sensitivity and moderate-to-good specificity in detecting patients with <45mL/min/1.73m2; below this level, it has been shown that the risk of contrast-induced nephropathy increases significantly, making it an effective screening tool. [24]
One important caveat: PCI has its own separate risk scoring system.
Once risk is assessed, patients broadly fall into three groups:
- Low risk - Proceed with the scan.
- Intermediate to high risk -
- If benefit > harm → proceed (with appropriate precautions if needed)
- If harm > benefit → consider alternative imaging or strategies
Basically, you are asking: “Is this scan important enough to justify the risk?”
Step 3: What can we do to reduce risk?
1. Choice of iodinated contrast media
- Use Iso-osmolar or Low-osmolar contrast media (KIDGO 2026)
- Use the lowest possible dose required for adequate imaging (KIDGO 2026)
2. Volume expansion
- Initiate peri-procedural volume expansion with 0.9% NS before contrast study if feasible (KIDGO 2026)
No high certanity evidence.
However, in the dehydrated state, renal blood flow and GFR are decreased, the effect of iodinated contrast medium may be accentuated, and there is a theoretical concern of prolonged tubular exposure to iodinated contrast medium due to low tubular flow rates.
3. Other aspects (KIDGO 2026)
- Withhold all non-essential nephrotoxic drugs
- Other drugs that have been considered but not found to be useful are
- N-acetylcysteine
- Ascorbic acid
- Furosemide
- Dopamine
- Fenoldopam
- Calcium channel blockers
- Sodium bicarbonate
- Prophylactic hemodialysis is potentially harmful
What Matters…
Before deciding to wait for a creatinine report to do a CT in the ED, ask these questions
1️⃣ Is it an emergency scan?
If contrast media administration is required for a life-threatening diagnosis, then it should not be withheld based on kidney function
2️⃣ Is there an indication to do a creatinine?
ACR 2025 guidance suggests renal function assessment before the intravascular administration of iodinated contrast medium for these patients when done in the ED
- Personal history of renal disease
- History of diabetes mellitus (optional)
- Metformin or metformin-containing drug combinations
Since many ED patients are unaware of their renal status, consider using the Choyke questionnaire to identify patients with a higher risk of abnormal renal function
- Has any doctor ever told you that you have kidney problems?
- Has any doctor ever told you that you have protein in your urine (proteinuria)?
- Do you have high blood pressure (hypertension)?
- Do you have diabetes?
- Do you have gout?
- Have you ever had kidney surgery?
If any of these is true, it is reasonable to wait for the creatinine report.
3️⃣Is the patient anuric?
Patients with anuric end-stage kidney disease can receive contrast without risk of further renal damage because there’s essentially no residual kidney function to lose.
If not → it is important to remember that CKD is only a relative contraindication to contrast-enhanced scans.
- Discuss alternate methods of diagnosis
- If deciding to proceed, consider methods to minimise possible CI-AKI
Want to Read More?
- Mehran, Roxana, George D. Dangas, and Steven D. Weisbord. "Contrast-associated acute kidney injury." New England Journal of Medicine 380.22 (2019): 2146-2155.
- Biondi-Zoccai, Giuseppe, et al. "Nephropathy after administration of iso-osmolar and low-osmolar contrast media: evidence from a network meta-analysis." International journal of cardiology 172.2 (2014): 35-380.
- Fom, Aaron M., et al. "Iodixanol versus low-osmolar contrast media for contrast-induced nephropathy: meta-analyses of randomised, controlled trials." Circulation: Cardiovascular Interventions 3.4 (2010): 351-358.
- McDonald, Jennifer S., et al. "Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis." Radiology 267.1 (2013): 119-128.
- McDonald, Jennifer S., et al. "Risk of intravenous contrast material–mediated acute kidney injury: a propensity score–matched study stratified by baseline-estimated glomerular filtration rate." Radiology 271.1 (2014): 65-73.
- McDonald, Robert J., et al. "Intravenous contrast material–induced nephropathy: causal or coincidental phenomenon?" Radiology 267.1 (2013): 106-118.
- Hinson, Jeremiah S., et al. "Risk of acute kidney injury after intravenous contrast media administration." Annals of emergency medicine 69.5 (2017): 577-586.
- Hinson, Jeremiah S., et al. "Acute kidney injury following contrast media administration in the septic patient: a retrospective propensity-matched analysis." Journal of Critical Care 51 (2019): 111-116.
- Ehrmann, Stephan, et al. "Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis." Intensive care medicine 43.6 (2017): 785-794.
- Azzouz, Manal, Janne Rømsing, and Henrik S. Thomsen. "Fluctuations in eGFR in relation to unenhanced and enhanced MRI and CT outpatients." European journal of radiology 83.6 (2014): 886-892.
- Kooiman, J., et al. "No Increase in Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin Excretion Following Intravenous Contrast Enhanced-CT." European Radiology, vol. 25, no. 7, July 2015, pp. 1926–1934. doi:10.1007/s00330-015-3624-4.
- McDonald, Jennifer S., et al. "Risk of acute kidney injury, dialysis, and mortality in patients with chronic kidney disease after intravenous contrast material exposure." Mayo Clinic Proceedings. Vol. 90. No. 8. Elsevier, 2015.
- Too, C. W., et al. "Screening for impaired renal function in outpatients before iodinated contrast injection: comparing the Choyke questionnaire with a rapid point-of-care-test." European journal of radiology 84.7 (2015): 1227-1231.
Made with Bullet